Simufilam - Filana Therapeutics
Alternative Names: C0105; C0105M; Filora; PTI-125; PTI-910; Simufilam hydrochloride; Sumifilam - Filana TherapeuticsLatest Information Update: 12 May 2026
At a glance
- Originator Pain Therapeutics
- Developer Filana Therapeutics
- Class Antidementias; Antiepileptic drugs; Ketones; Small molecules
- Mechanism of Action FLNA protein modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Epilepsy
- Discontinued Alzheimer's disease
Most Recent Events
- 05 May 2026 Filana Therapeutics plans to submit responses including additional pre-clinical data and protocol design modifications for Epilepsy to the US FDA and expects to provide a program update in the coming months
- 15 Apr 2026 Pharmacodynamics data from preclinical study in Epilepsy released by Filana Therapeutics
- 10 Mar 2026 Cassava Sciences is now called Filana Therapeutics